Skip to content

Scailyte closed today their pre-series A financing

Scailyte closed their pre-series A financing round with CHF 3.7 million led by Swisscom Ventures, 4FO ventures, Hemex and Investiere.

Scailyte™ is delighted to welcome investiere as an additional investor just before closing the pre-series A financing round.™

Today, Scailyte closed their pre-series A financing round with CHF 3.7 million led by Swisscom Ventures, joined by 4FO ventures, a private investor, Hemex and Investiere. This pre-series A financing round will allow Scailyte to develop faster their assays in the rapid-emerging single-cell data technology field. The raised capital will be used to further build upon Scailyte’s biomarker and IVD pipeline and for the development of the first clinical applications using single-cell biomarkers.

Scailyte is honored to have investiere among their renowned investor base. The additional financing increases the opportunities for Scailyte to develop in-vitro diagnostics using single-cell technologies and their proprietary single-cell data analysis platform ScaiVision™.

“We are continuously developing and utilizing our data analytics platform ScaiVision™ for biomarker discovery from single-cell data” says Peter Nestorov, CEO of Scailyte AG. “The current version covers all aspects of processing, handling and interpreting single-cell proteomics data (mass and flow cytometry), as well as a core functionality for analysing single-cell transcriptomics data. This allows us to accelerate biomedical discovery and enable the next generation of precision diagnostics. With the support of strong partners like Swisscom Ventures, 4FO and HEMEX, we will continue to grow in the fast-emerging single-cell analysis field, enabling various clinical applications of single-cell data “.

“Scailyte has a strong product pipeline. It includes candidates for biomarkers for Endometriosis and CTCL with a market potential of several hundred million Francs for each of these diagnostics. Furthermore, Scailyte enjoys strong support in the medical expert community” says Susanne Schorsch, Investment Manager at investiere.

investiere provides exclusive access to start-up investments to qualified private and institutional investors. investiere is one of the most active startup investors in Switzerland, backed by business angels as well as ZKB with more than 90 investments.

Scailyte AG was founded in Luzern, Switzerland in July 2017. Scailyte is an ETH Zurich spin-off and is supported by Innosuisse (Swiss Innovation Agency). The company has gained recognition by winning several national and international start-ups competitions and is the beneficiary of significant research grants. Scailyte has a multi-disciplinary team with expertise in Cell biology, Genetics, Artificial Intelligence, Software development, Finance, Marketing and Sales. Scailyte discovers ultrasensitive biomarkers and develops in-vitro diagnostics using single-cell technologies and their proprietary single-cell data analysis platform ScaiVision™. ScaiVision™ offers best-in-class analysis of complex single-cell data to enhance biomedical research, pharmaceutical discovery, and precision diagnostics. Besides developing its own in vitro diagnostic (IVD) applications, Scailyte also offers its biomarker discovery services to companies aiming to complement and enrich their analysis by adding the single-cell perspective.

The ScaiVision™ biomarker discovery platform delivers best-in-class performance for supervised pattern recognition analysis of single-cell data. The performance and clinically relevant application of the core deep learning algorithm of ScaiVision have been validated in several scientific papers and have resulted in patent-pending diagnostic applications. For more information visit www.scailyte.com

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

NextGen Omics Boston Conference

Scailyte will be attending the upcoming NextGen Omics Boston conference, taking place on March 30-31

Read more

Recent News

Vijay Tiwari is appointed as Chair of the Scientific Advisory Board

Vijay Tiwari is appointed as the Chair of Scailyte's Scientific Advisory Board

Read more

Recent News

Endometriosis interview series

We mark Endometriosis Awareness Month, and Scailyte is proud to support this cause with the “Endom

Read more

Recent News

Scailyte Announces a Collaboration with Turnstone Biologics

Scailyte Announces Collaboration with Turnstone Biologics to Identify Biomarker Signatures in Solid

Read more

Recent News

BIO-Europe Spring 2023

We will be attending the 17th annual BIO-Europe Spring taking place from 20-22 March 2023 in Basel.

Read more

Recent News

Deciphering Disease Mechanisms Through Functional Genomics

Tiwari lab studies gene-epigenetic interplay in cell identity & its disruption in cancer/neurologica

Read more

Recent News

International Women's Day 2023

Scailyte celebrates International Women’s day and praises all women Scailyters: smart, trailblazin

Read more

Recent News

Diana Stoycheva and Sarah Carl at Biomarkers 2023

We are excited to announce our attendance at Oxford Global Conferences' Biomarkers 2023! Our team, i

Read more

Recent News

01 /04

NextGen Omics Boston Conference

Scailyte will be attending the upcoming NextGen Omics Boston conference, taking place on March 30-31

Read more

Vijay Tiwari is appointed as Chair of the Scientific Advisory Board

Vijay Tiwari is appointed as the Chair of Scailyte's Scientific Advisory Board

Read more

Recent News

02 /04

Endometriosis interview series

We mark Endometriosis Awareness Month, and Scailyte is proud to support this cause with the “Endom

Read more

Scailyte Announces a Collaboration with Turnstone Biologics

Scailyte Announces Collaboration with Turnstone Biologics to Identify Biomarker Signatures in Solid

Read more

Recent News

03 /04

BIO-Europe Spring 2023

We will be attending the 17th annual BIO-Europe Spring taking place from 20-22 March 2023 in Basel.

Read more

Deciphering Disease Mechanisms Through Functional Genomics

Tiwari lab studies gene-epigenetic interplay in cell identity & its disruption in cancer/neurologica

Read more

Recent News

04 /04

International Women's Day 2023

Scailyte celebrates International Women’s day and praises all women Scailyters: smart, trailblazin

Read more

Diana Stoycheva and Sarah Carl at Biomarkers 2023

We are excited to announce our attendance at Oxford Global Conferences' Biomarkers 2023! Our team, i

Read more

Recent News